Overall, the combination of LXH254 plus trametinib demonstrated overall better anti-tumor activity in our four xenograft models of NF1-MPNST through greater inhibition in ERK and cell cycle signaling, and subsequent reduction in tumor proliferation. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.